Our partners and attorneys are highly qualified and highly experienced to advise you in all areas of Intellectual Property law. We advise start-ups, SMEs, and multinational corporations and ensure that your inventions, brands and designs are expertly protected.
All of the Partners & People of AA Thornton are joining forces with Venner Shipley
The World Intellectual Property Organization (WIPO) and the International Federation of Pharmaceutical Manufacturers and Associations (IFPMA), together with 20 participating global pharmaceutical companies, have joined forces to globalise the concept of the US’s ‘Orange Book’.
Most drugs have one or more brand names (trade marks, often called the ‘invented name’); and an INN (or international non-proprietary or ‘generic’ name), which identifies the active pharmaceutical ingredient(s). INNs are registered with the World Health Organization (WHO). For example, the non-prescription pain reliever known widely by its INN, ibuprofen, also goes by multiple trade marks such as Advil, Motrin, Brufen, Nurofen, and others. A patent application to protect the innovator from ‘copying’ of the drug by others is usually drafted many years before the INN is agreed, so the patent specification usually does not refer to the INN (or the trade mark, for similar reasons), resulting in a lack of linkage between patent language and regulatory or marketing language used for the drug concerned.
Pat-INFORMED aims to solve this problem by linking patent information worldwide with the INN for important medicines. However, trade marks are not included.
Presently, the database is searchable by INN and country. Results appear in a simple table having three columns: INN, Participant (company), and Patents, which provides the title of the patent.
Clicking on a patent title opens a ‘card’, which provides an informal summary of the patent plus basic information on the patent in each territory. This information includes the patent’s
publication number and date, plus filing date. Where the patent specification is available in WIPO’s Patentscope database of international and patent collections, a link to that is provided. The ‘health warning’[3] on the card should be carefully noted: Pat-INFORMED is not intended to be a short-cut to a comprehensive patent status report and should not solely be relied upon for legal purposes. A Patent Attorney can advise further and comprehensively on such matters.
Participation in Pat-INFORMED is voluntary and not all drugs are covered.
So far, 20 pharmaceutical companies have committed to contributing to the database:
| AbbVie (USA) | Leo Pharma (Denmark) |
| Astellas Pharma Inc. (Japan) | Lilly (USA) |
| Bristol-Myers Squibb (USA) | Merck KGaA (Germany) |
| Daiichi-Sankyo (Japan) | MSD / Merck & Co., Inc. (USA) |
| Eisai (Japan) | Novartis (Switzerland) |
| Gilead Sciences, Inc. (USA) | Novo Nordisk (Denmark) |
| GlaxoSmithKline (GSK) (United Kingdom) | Pfizer (USA) |
| IPSEN (France) | Roche (Switzerland) |
| Johnson & Johnson (USA) | Shionogi Inc. (Japan) |
| Takeda (Japan) | UCB (Belgium) |
Participants are committed to disclosing their main patents in every country in which they are granted and details of all therapies presently covered by the database.
Pat-INFORMED contains patent information from these companies on drugs which are on the WHO Essential Medicines List; this information will be updated every six months.
Other important drugs are included from the oncologic, hepatitis C, cardiovascular, HIV, diabetes and respiratory therapy areas. Eventually, all therapy areas will be covered. Information on these drugs will be updated annually.
The possibility of including other treatments, complex therapies and vaccines will be explored in due course.
[1] Available at: http://www.wipo.int/wipo_magazine/en/2018/05/article_0006.html?utm_source=WIPO+Newsletters&utm_campaign=0d17ff72ab-EMAIL_CAMPAIGN_2018_08_07_01_29_COPY_01&utm_medium=email&utm_term=0_bcb3de19b4-0d17ff72ab-256645573)
[2] Available at: http://www.wipo.int/pat-informed/en/
[3] “Pat-INFORMED is not intended as a replacement for a freedom-to-operate analysis, is not free of errors, and should not be relied upon as a comprehensive inventory of patent information. Pending applications are not listed, and in certain cases licensing arrangements or other factors may prevent Participants from listing patents. Use of Pat-INFORMED is subject to its Term of Use and Disclaimers”
Category: Latest Insights | Published: | Read more
